MedTrace Logo

Efficacy and Safety Profile of Cisatracurium Besylate for IAH

NCT05172531 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-07-22

No results posted yet for this study

Summary

This study is a randomized, double-blinded, controlled design. In this study, Cisatracurium Besylate was selected for treatment in Intra-abdominal hypertension or abdominal compartment syndrome,accompanied with evaluating the effects on the duration of organ failure,length of hospital stay and mortality.To clarify the effect of Cisatracurium Besylate on IAH/ACS is of great significance to the clinical applications.

Conditions

  • Intra-abdominal Hypertension

Interventions

DRUG

Cisatracurium Besylate

Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。

DRUG

saline 0.12ml/kg/hr

saline 0.12ml/kg/hr

Sponsors & Collaborators

  • Tianjin Nankai Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2023-01-30
Completion
2023-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172531 on ClinicalTrials.gov